Center for Molecular Medicine and Immunology, 300 The American Road, Morris Plains, NJ 07950, USA.
Expert Opin Biol Ther. 2012 Sep;12(9):1173-90. doi: 10.1517/14712598.2012.693472. Epub 2012 Jun 1.
Over a half a century ago, radiolabeled antibodies were shown to localize selectively in tissues based on the expression of unique antigens. Antibodies have since become the de facto targeting agent, even inspiring the development of non-antibody compounds for targeting purposes.
In this article, we review various aspects of how antibodies are transforming the way cancer is being detected and treated, with the growing demand for unconjugated and many new antibody conjugates. While unconjugated antibodies continue to garner most of the attention, interest in new antibody drug conjugates and immunotoxins has expanded over the past few years. However, there continues to be active research with new radioimmunoconjugates for imaging and therapy, particularly with α-emitters, as well as antibody-targeted cytokines and other biological response modifiers.
The increasing number of new agents being developed and tested clinically suggests that antibody-targeted compounds will have an expanding role in the future.
半个多世纪以前，放射性标记的抗体被证明可以根据独特抗原的表达选择性地在组织中定位。此后，抗体已成为事实上的靶向药物，甚至激发了用于靶向目的的非抗体化合物的发展。
在本文中，我们综述了抗体如何改变癌症检测和治疗方式的各个方面，越来越多的人需要未缀合的和许多新的抗体缀合物。虽然未缀合的抗体继续吸引大部分关注，但近年来对新的抗体药物偶联物和免疫毒素的兴趣有所扩大。然而，人们仍在积极研究新的放射性免疫偶联物用于成像和治疗，特别是α-发射体，以及抗体靶向细胞因子和其他生物反应调节剂。
越来越多的新制剂正在开发和临床测试，这表明抗体靶向化合物在未来将发挥更大的作用。
